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Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms 
with variable risk of evolution into post-PV and post-ET myelofibrosis, from now on referred to as 
secondary myelofibrosis (SMF). No specific tools have been defined for risk stratification in SMF. 
To develop a prognostic model for predicting survival, we studied 685 JAK2, CALR, and MPL 
annotated patients with SMF. Median survival of the whole cohort was 9.3 years (95% CI: 8-not 
reached-NR-). Through penalized Cox regressions we identified negative predictors of survival and 
according to beta risk coefficients we assigned 2 points to hemoglobin level <11 g/dL, to 
circulating blasts ≥3%, and to CALR-unmutated genotype, 1 point to platelet count <150 x 109/L 
and to constitutional symptoms, and 0.15 points to any year of age. MYSEC-PM (Myelofibrosis 
Secondary to PV and ET-Prognostic Model) allocated SMF patients into four risk categories with 
different survival (P < 0.0001): low (median survival NR; 133 patients), intermediate-1 (9.3 years, 
95% CI: 8.1-NR; 245 patients), intermediate-2 (4.4 years, 95% CI: 3.2-7.9; 126 patients), and high 
risk (2 years, 95% CI: 1.7-3.9; 75 patients). Finally, we found that the MYSEC-PM represents the 
most appropriate tool for SMF decision-making to be used in clinical and trial settings. 
 





Polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF) are the 
classical BCR/ABL1-negative myeloproliferative neoplasms (MPN).1, 2 The two more indolent 
diseases, PV and ET, nevertheless, can progress to secondary myelofibrosis (SMF), named post-PV 
(PPV) MF and post-ET (PET) MF,3 and to blast phase (BP),4 that result in worsening survival.5 
 
Because of the lack of information on SMF, PMF and SMF are considered similar. The IPSS 
(International Prognostic Scoring System)6 and its time-dependent variants (Dynamic IPSS –DIPSS 
and DIPSS-plus)7, 8 are often used to predict survival and to plan therapy for SMF patients. 
However, these models have been developed in patients with PMF and are suboptimal to predict 
survival in SMF.9-11 Recently, having acquired the prognostic implication of phenotype driver 
mutations and of additional mutations, the prognostication in MPN is moving towards integrated 
clinical-molecular models. 12-16  
 
The MYSEC (MYelofibrosis SECondary to PV and ET) project recently disclosed genotype-
phenotype associations in the largest cohort of SMF patients published to date, including 685 
patients.17 We found that at presentation JAK2-mutated patients had higher white blood cell 
count and greater splenomegaly than CALR-mutated patients and that CALR type 1/type 1-like and 
CALR type 2/type 2-like were similar in terms of clinical presentation and outcome.  Blast phase 
incidence was higher in JAK2-mutated PET MF and TN patients (triple negative, i.e. without JAK2, 
MPL, CALR mutations) when compared with CALR-mutated patients.  
 
In this study, based on the MYSEC database, we developed an integrated clinical-molecular model 
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 4 
SUBJECTS AND METHODS 
 
Study population 
This study includes 781 patients collected from 16 international centers (Table 1S). All patients 
have demographic, clinical, and hematologic data at diagnosis and an adequate follow-up. No 
differences in disease presentation (white blood cell count, hemoglobin level, platelet count) were 
observed among centers applying the Kruskal Wallis and pairwise Wilcoxon rank-sum tests. Driver 
mutation status was requested as secondary objective and available in 685 patients. Diagnoses of 
PPV MF and PET MF were performed between 1981 to 2015 and were locally reviewed according 
to the International Working Group on Myeloproliferative Neoplasm Research and Treatment 
(IWG-MRT) criteria.3 Evolution to BP was defined when leukemic blast cells were more than 20%, 
according to the World Health Organization (WHO) criteria.18 The study was approved by the 
Institutional Review Board of each Institution and conducted in accordance with the principles of 
the Declaration of Helsinki. 
 
Statistical analysis 
Descriptive summaries are reported as median and range for continuous covariates, and count 
and relative frequency for categorical ones. Continuous baseline values were compared via non-
parametric Mann-Whitney U tests; categorical feature counts were compared with Fisher’s exact 
tests.  Time-to-event analyses were performed via Kaplan-Meier curves, using log-rank tests for 
comparisons and semi-parametric Cox models for regression. Events were assumed to be death 
for any cause (censored at last follow-up or at the time of stem cell transplant), thrombosis and 
leukemia. P values <.05 (2-tailed) were considered significant. To test impact on survival, we first 
performed an exploratory univariate analysis developing Cox regression models considering each 
covariate separately. To account for possible nonlinear effects, restricted cubic spline with 3 nodes 
were considered for continuous predictors. To select a parsimonious set of covariates on which to 
base the prediction algorithm, we fitted regularized regression models according to the least 
absolute shrinkage selection operator (LASSO) method, entering all the available discretized 
covariates. The selected value of the regularization parameter was λ = 0.053. LASSO fits a 
sequence of models with varying degrees of penalization in order to shrink less-relevant 
coefficients to zero, thus effectively performing a variable selection.19 The performance of the 
models was evaluated with 10-fold cross-validation; the highest shrinkage factor providing 
©    2017 Macmillan Publishers Limited. All rights reserved.
 
 5 
performance within one standard deviation of the optimal cross-validated one was selected.20 The 
ability of the final score to discriminate survival was verified via Harrell’s concordance index C and 




Presenting features at diagnosis of SMF, comparison of PET MF and PPV MF 
We developed the analyses on 685 (333 PET MF, 352 PPV MF) SMF patients with phenotype driver 
mutations available. Demographics and clinical features of patients at onset of SMF are shown in 
Table 1. Patients with PPV MF were older, had higher values of white blood cells and hemoglobin, 
larger spleen size and lower platelet count than those with PET MF. Pearson pairwise test 
demonstrated that at diagnosis patients with PPV MF had significantly higher frequency of 
constitutional symptoms, abnormal karyotype and prior thrombosis than those with PET MF. A 
significantly higher number of PPV MF patients had received cytoreductive treatments (231 with 
PET MF, 287 PPV MF, P < .001). 
 
Events occurring after diagnosis of SMF 
Incidence rates of events are reported in Table 2. For their calculation we took into account death 
and stem cell transplant as competing risks with thrombosis and leukemia. In detail, thrombotic 
events occurred in 67 SMF (12%; 29 PET MF and 38 PPV MF), blast phase in 52 SMF (7.5%, 30 PET 
MF and 22 PPV MF) and death in 169 SMF (25%, 69 PET MF and 100 PPV MF). Cause of death was 
known in 136 of the 169 patients who died: non-clonal disease progression in 52 (38%), blast 
phase in 43 (32%), second malignancy in 10 (7%), infection in 12 (9%), heart failure in 11 (8%), 
vascular complications in seven (5%), and other in one (1%). Median survival was 14.5 years (95% 
CI: 8-NR) in PET MF and 8.1 years (95% CI: 7.2-10.1) in PPV MF, with a borderline difference 
(Supplemental Figure 1, log-rank test, P = .051).  
 
Analysis of survival and identification of risk factors 
Median survival of SMF was 9.3 years (95% CI: 8-NR), as illustrated in Figure 1. To ascertain 
whether SMF survival has increased over calendar years, we performed a Cox regression including 
calendar year of diagnosis (as a linear covariate), correcting for IPSS risk category. We found that 
the trend of survival was not significantly changed (P = .064). 




Univariate Cox Proportional Hazards regression showed that advanced age, male gender, lower 
hemoglobin level, greater white blood cell count, lower platelet count, higher circulating blast 
count, bone marrow fibrosis grade 3 vs. grade 2, presence of constitutional symptoms (fever, 
weight loss, night sweats), history of thrombosis before SMF, longer time from ET/PV to SMF 
negatively affected survival (maximum P values = .004). Interestingly, a normal karyotype was 
associated with longer survival (P = .001), but, as cytogenetic data were available in only 340 
patients (49%), we excluded this variable from the statistical analysis. Conversely, type of 
diagnosis (PET MF, PPV MF), centers, spleen and liver size were neutral for survival. 
 
Analysis of cutpoints of continuous variables indicated marked differences for patients with white 
blood cell count higher than 25 x109/L, hemoglobin value lower than 11 g/dL, platelet count lower 
than 150 x109/L, circulating blast equal to or higher than 3% and time to SMF greater than 10 
years (P < .0001 each). An exploratory multi-class regression showed that HRs (hazard ratios) for 
CALR-unmutated genotypes (i.e, JAK2-mutated, MPL-mutated and triple negative) had overlapping 
confidence intervals, and significantly different from CALR-mutated genotype (P = .003), thus 
determining a binary category (CALR-mutated vs. CALR-unmutated) for genotype. Multivariate 
models consistently showed age at diagnosis to be an important predictor for survival (P < 
0.0001). In order to minimize information loss on this covariate, we retained age at diagnosis as a 
continuous covariate. 
 
We then selected the significant covariates employing a LASSO Cox regression. Six covariates 
remained with non-null coefficients: advanced age, hemoglobin level below 11 g/dL, platelet 
count below 150 x109/L, circulating blasts equal to or higher than 3%, CALR-unmutated genotype, 
presence of constitutional symptoms.  We generated a final Cox regression model incorporating 
the identified covariates (Table 3). All coefficients remained highly significant (P < .003); a test for 
Schönfeld residuals revealed no deviations from the proportional hazards assumption, except for a 
minor departure for constitutional symptoms.21 
 
  
©    2017 Macmillan Publishers Limited. All rights reserved.
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Development of the prognostic model  
All factors shown in Table 3 were therefore included in the MYSEC-PM. To simplify the application 
of the risk score, we rounded the risk coefficients as risk points (Table 3). Namely, we allocated 
two points to hemoglobin level below 11 g/dL, to circulating blasts equal to or higher than 3% and 
to CALR-unmutated genotype, one point to platelet count lower than 150 x109/L and to the 
presence of constitutional symptoms. Age-related risk was rescaled accordingly, yielding 
approximately 0.15 points per year. 
 
We thus recoded the MYSEC-PM into four categories of adequate size by pooling consecutive 
score values. The resulting risk categories were: low-risk (score less than 11, 133 patients), 
intermediate-1 risk (score equal to or higher than 11 and lower than 14, 245 patients), 
intermediate-2 risk (score equal to or higher than 14 and less than 16, 126 patients) and high risk 
(score equal to or higher than 16, 75 patients). Survival was significantly different among the risk 
groups (Figure 2A, log-rank test P < 10-6). Median survival was not reached in the low risk, 9.3 
years (95% CI: 8.1-NR) in the intermediate-1 risk, 4.4 (95% CI: 3.2-7.9) in the intermediate-2 risk 
and 2 years (95% CI: 1.7-3.9) in the high risk category. Additional Figure 2 shows survival compared 
to year-, age- and sex-matched U.S. population. Taking low risk as reference, the estimated 
average HR for intermediate-1 risk was 3.6 (95% CI: 1.8-7.2), for intermediate-2 risk was 10.6 (95% 
CI: 5.3-21.1) and that for high risk was 29.1 (95% CI: 14.1-59.8).  When used to assign patients to 
the four discrete risk categories, the test retained very good predictivity (cross-validated C 
statistics 0.79) and calibration.  
 
We validated the MYSEC-PM risk score via the internal 40-fold cross-validation of Harrell’s 
concordance index, or C-statistic; the procedure re-trains the model multiple times on random 
resamples of the original data, aggregating the corresponding values obtained for C.  The resulting 
cross-validated value of the C-statistics was C = 0.78 (cf. C = 0.79 of the full data set), confirming 
the validity of the model.  
 
How to use the prognostic model in clinical practice: the MYSEC PM nomogram 
Given the hybrid nature (continuous age, discrete points) of the risk prediction model, we provide 
a discrete/continuous nomogram (Figure 2B) to interpolate the final score and assess the 
individual patient’s risk in an easy manner. The MYSEC PM nomogram provides an at-a-glance 
©    2017 Macmillan Publishers Limited. All rights reserved.
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diagram to combine the effect of age (continuous) and other covariates, at the same time 
providing color-coded read-outs on the resulting risk category. To calculate the MYSEC-PM doctors 
have to: 1) collect information on non-age prognostic variables (hemoglobin value, platelet count, 
circulating blast counts, genotype, constitutional symptoms), thus refer to Table 3 to assign the 
points and calculate their sum (score); 2) collect patient’s age; 3) use the nomogram (Figure 2B) to 
locate the combination of score (read on the vertical axis) and age (on the horizontal axis) – the 
color at the location indicates the final risk category, 3) estimate the individual survival on the 
Kaplan Mayer curve (Figure 2A). To further illustrate and expedite the use of the score, the 
nomogram is also made available as an interactive web application for desktop and mobile use 
(available online at https://mysec.shinyapps.io/prognostic_model/). 
 
Mutation status distribution in the MYSEC-PM risk categories 
Supplemental Figure 3 describes the distribution of the phenotype driver mutations in the four 
MYSEC-PM risk groups. Of interest, CALR mutations were absent in high risk patients. 
 
Comparison of the MYSEC-PM with the IPSS  
We compared the quality on the risk stratification of the MYSEC-PM prognostic model with 
respect to the previously used IPSS (developed in PMF). The MYSEC-PM risk categories had higher 
predictive values than IPSS both in the original data set (C = 0.79 for MYSEC-PM and C = 0.70 for 
IPSS) and the 40-fold validation (C = 0.78 for MYSEC-PM and C = 0.71 for IPSS). The same 
conclusion has been obtained considering Akaike information criterion (AIC) values for the two 
models, which amount to 1416 and 1485 respectively for MYSEC-PM and IPSS (preferable models 
have lower AIC values).  In summary, the predictive power of the MYSEC-PM is very high, and 
significantly better than the IPSS model.  
 
In addition, we also checked whether it was possible, for the sake of simplicity, to integrate the 
IPSS model with genotype, by fitting a Cox model including the IPSS risk factors augmented by the 
“not-CALR” covariate. In this analysis, leukocyte count > 25 x109/L ceases to be a significant 
predictor, suggesting that its adoption would require further changes to scores and thresholds 
with respect to the original IPSS. 
 
 





Diagnosis of SMF is based on the IWG-MRT criteria, established in 2008: an antecedent WHO-
based diagnosis of PV or ET including appropriate mutations and a bone marrow fibrosis above 
grade 1 are the two main criteria.3 The molecular anatomy of PV and ET has changed from 2008, 
leading to the new WHO classification in 2016.1 By enriching the MYSEC database with the 
phenotype driver mutations of the JAK2, CALR and MPL genes,1, 2 we provide a molecularly 
updated diagnosis of PV and ET and consequently of SMF. Concerning the accompanying 
mutations of MF,1 no impact on SMF survival has been demonstrated,22 differently from their 
effect in PMF.12 The assessment of bone marrow myelofibrosis requires bone marrow biopsy. Our 
study is representative of real-life in Europe and the United States: doctors perform bone marrow 
biopsy when they suspect disease evolution, an approach that remains a mainstay in recent 
recommendations.23 Of note, the MYSEC database showed that the longer the span between 
PV/ET diagnosis and SMF, the worse the survival. This suggests to carefully monitor PV/ET patients 
in order to identify SMF evolution earlier, especially if disease-modifying treatments may be 
envisaged. In our series, we cannot completely exclude that some ET are prefibrotic/early MF 
(WHO, 2016).1 
 
The MYSEC study also characterized clinical phenotype and events of SMF. PPV MF and PET MF 
had substantial differences in clinical presentation, with a more “proliferative” phenotype in PPV 
MF, a pattern that is confirmed by the higher rate of PPV MF patients receiving cytoreductive 
agents. Of interest, the incidence of thrombosis ranged from 2.4 to 3.1 / 100 patients-year in PET 
MF and PPV MF, respectively, and accounted for 5% of deaths. These data clearly indicate that the 
risk of vascular complications is still significant in SMF. Perhaps, thromboprophylaxis should be 
considered in SMF, if not contraindicated because of a bleeding history or a low platelet count. 
 
The median survival in SMF was 9.3 years without significant differences between PPV MF and PET 
MF. The MYSEC dataset did not disclose any change of SMF survival over calendar years of 
diagnosis. This seems to suggest that treatment strategies have not changed the disease history 
yet. Modern approach to myelofibrosis treatment includes the use of JAK inhibition and allogenic 
stem cell transplantation (ASCT).24 In PMF, we demonstrated that ruxolitinib might modify life 
expectancy in higher risk categories25 with some criticisms26-28 and that  ASCT improves survival in 
©    2017 Macmillan Publishers Limited. All rights reserved.
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higher risk categories, with the opposite effect in low risk patients,29 when matched with a cohort 
of conventionally treated individuals. To date, no information is available on survival effect of 
these strategies in SMF. 
 
Concerning current risk stratification of patients with SMF, the IPSS6 and DIPSS8 prognostic models 
are used in clinical practice23 as well as in clinical trials.30-34 Introducing the MYSEC-PM instead of 
the IPSS model in patients with SMF will provide strong advantages: 1) model development in the 
correct setting of patients: IPSS/DIPSS were generated in PMF and not SMF, and, as a 
consequence, their application outside that setting is arbitrary and not data-supported; 2) the 
integrated clinical-molecular MYSEC-PM provides an excellent discrimination of survival (C=0.79), 
much better than the clinical-based IPSS; 3) a tentative integrated approach we did combining IPSS 
risk factors with mutational status failed in SMF.  
 
Advanced age, hemoglobin level below 11 g/dL, platelet count below 150 x109/L, circulating blast 
cells equal to or greater than 3%, CALR-unmutated genotype and the presence of constitutional 
symptoms are the risk factors composing the MYSEC-PM. Advanced age, anemia, circulating blast 
cells and the presence of constitutional symptoms are both components of the MYSEC-PM and the 
IPSS model,6 and advanced age and constitutional symptoms also stratify patients at the time of 
ASCT for survival.35 This indicates a role of these factors in myelofibrosis survival prediction in 
general.  
 
Myelofibrosis is an age-related disease and advanced age is the most powerful prognostic factor 
for survival prediction. This is not surprising from a biological standpoint as hematopoietic stem 
cells are modified during aging influencing disease development and eventually favoring clonal 
hematopoiesis with selection of mutated cells.36 It is noteworthy that the most frequently 
involved age-related somatic mutations (DNMT3A, TET2, ASXL1, and JAK2)37 are also implicated in 
myelofibrosis development.12  
 
The extended study of the three phenotype driver mutations helped to recognize the favorable 
impact on survival of CALR mutations,17 and in this latter analysis CALR-unmutated genotypes 
(JAK2-mutated, MPL-mutated, triple negativity) are associated with a worse survival in 
multivariable analysis. The association of CALR mutations with a benign outcome in SMF, also 
©    2017 Macmillan Publishers Limited. All rights reserved.
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highlighted by the absence of CALR-mutated patients within the MYSEC-PM high-risk group, 
remains to be determined. Although all phenotype driver mutations activate the JAK/STAT 
pathway, subtle changes in the activation mechanism have been described among mutants.38 The 
molecular profiling of SMF patients allows the MYSEC-PM to improve risk stratification in SMF, as 
demonstrated by the superior accuracy in survival prediction of MYSEC-PM over IPSS. 
 
The MYSEC-PM identifies four risk categories with different survival: median survival was not 
reached in the low risk, 9.3 years in the intermediate-1 risk, 4.5 years in the intermediate-2 risk 
and 2 years in the high risk category. This information may be directly translated into clinical 
practice to personalize treatment options. Young and fit patients with intermediate-2 and high risk 
disease can be considered candidates for ASCT on the basis of the European LeukemiaNet 
recommendations,23 which give an indication for ASCT in MF patients with a life expectancy below 
five years. On the opposite, patients at low risk have an indolent disease and a more conservative 
approach seems reasonable. Patients at intermediate-1 risk should be discussed on an individual 
basis in SMF. Ruxolitinib can be offered on the basis of the national indication/reimbursement 
rules since it has been intensively studied in SMF patients with intermediate and high risk disease 
according to clinical-based prognostic models.31, 32 Concerning investigative clinical trials, the use 
of MYSEC-PM in the selection of SMF patients may help in the identification of patients at higher 
risk who may be candidates for new treatment strategies or at lower risk who may be candidates 
for preventive approaches targeting disease progression/survival. 
 
In conclusion, the MYSEC-PM is an integrated clinical-molecular prognostic model uniquely 
developed in SMF patients with a superior accuracy over IPSS.  This clearly indicates that the 
MYSEC-PM is appropriate to make a clinical decision or design new clinical trials for patients with 
SMF. 
  
©    2017 Macmillan Publishers Limited. All rights reserved.
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Legend to Figures  
 
Figure 1. Estimate of survival in 685 patients with post polycythemia vera and post essential 
thrombocythemia myelofibrosis. This represents the estimate of survival of the entire cohort of 
patients with secondary myelofibrosis. 
 
Figure 2. The MYSEC-PM. (A) The MYSEC-PM estimate of survival in patients with secondary 
myelofibrosis molecularly annotated for JAK2, CALR, MPL mutations. Risk factors and relative 
points composing the MYSEC-PM are patient’s age (0.15 per patient’s year of age), hemoglobin 
level below 11 g/dL (2 points), platelet count lower than 150 x109/L (1 point), circulating blasts 
equal to or higher than 3% (2 points), presence of constitutional symptoms (1 point) and CALR-
unmutated genotype (2 points). The final risk category is to be calculated with the MYSEC-PM 
nomogram (Figure 2B). The four risk categories are: low-risk (median survival not reached; 133 
patients), intermediate-1 risk (median survival 9.3 years, 95% CI: 8.0-NR; 245 patients), 
intermediate-2 risk (median survival 4.5, 95% CI: 3.2-7.9; 126 patients) and high risk (median 
survival 2.0 years, 95% CI: 1.7-3.9; 75 patients) (2). (B) The MYSEC-PM nomogram. The MYSEC PM 
nomogram visually assigns the MYSEC-PM risk category starting from the non-age prognostic 
variables (vertical axis) and the patient’s age (horizontal axis) illustrated in Table 3. To determine 
the risk category of an individual patient with hemoglobin value of 10 g/dL and circulating blast of 
6%, for example, follow the horizontal line, starting from the non-age-parameter-sum of 4 on the 
vertical axis (see Table 3 for points) to the age of the patient and record the color at that point. If 
the patient is 40 years old, the 4-line and the vertical 40-year line cross in the green field, 
corresponding to the low risk category, while if the patient is 70 years old, the 4-line and the 
vertical 70-year line cross in the violet field, corresponding to the intermediate-2 risk category. 
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Table 1. Hematological and clinical features of 685 patients with post essential 
thrombocythemia and post polycythemia vera myelofibrosis.  
 
SMF 
(n = 685) 
PET MF 
(n = 333) 
PPV MF 
(n = 352) 
P value 
Age, median (range), years 64 (25-96) 64 (25-93) 65 (34-96) .02 
Age older than 65 years, n. (%) 360 (53) 146 (44) 179 (51) .08 
Follow-up, median (range), years 3.0 (0.6-27.3) 3.1 (0.6-17.4), 2.9 (0.6-27.3) .88 
Time to SMF, years (range) 10.7 (0.6-41.4) 10.3 (0.7-34.8) 11.1 (0.6-41.4) .36 
History of cancer, n. (%) 87 (13) 36 (11) 51 (15) .16 
History of thrombosis, n. (%) 171 (26) 70 (22) 101 (29) .03 
Male gender, n. (%) 356 (52) 165 (50) 191 (54) .23 
WBC, median (range), x109/L 10.2 (1.1-98.4) 7.8 (1.1-97.3) 13.5 (1.7-98.4) < .001 
Hb, median (range), g/dL 11 (5-15.7) 10.7 (5-15.4) 12 (6.8-15.7) < .001 
PLT, median (range), x 109/L 336 (15-1908) 379 (40-1908) 294 (15-1689) < .001 
Circulating blast 3% or more (%) 55 (9) 24 (8) 31 (10) .43 
Spleen size,* median (range) 7 (0-34) 4 (0-27) 10 (0-34) < .001 
Constitutional symptoms, n. (%) 285 (44) 113 (37) 172 (51) < .001 
Normal karyotype,** n. (%) 223 (66) 118 (73) 105 (59) .005 
Favorable karyotype,** n. (%) 283 (87) 138 (88) 145 (85) .58 
JAK2 (V617F) 534 (78) 181 (54) 352(100) < .001 
CALR 102 (15) 102 (31) -  
MPL 30 (4) 30 (9) -  
Triple negative 19 (3) 19 (6) -  
SMF: secondary myelofibrosis; PET MF: post essential thrombocythemia myelofibrosis; PPV MF: post polycythemia 
vera myelofibrosis; WBC: white blood cell count; Hb: hemoglobin level; PLT: platelet count. 
*palpable from the left costal margin 
**Karyotype was available in 340 patients 
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Table 2. Incidence of events during the follow-up of 685 patients with post essential 
thrombocythemia and post polycythemia vera myelofibrosis. 
Incidence 
/100 patients-year (95% CI) 
PET MF 
(n = 333) 
PPV MF 
(n = 352) 
P value 
Thrombosis 2.4 (1.6-3.4) 3.1 (2.2-4.3) .2 
Blast phase 2.3 (1.6-3.4) 1.6 (1-2.5) .2 
Mortality 5.5 (4.3-7) 7.4 (6-8.9) .06 
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Table 3. Results of the multivariable analysis to define predictors of inferior survival in 685 
molecularly annotated patients with post essential thrombocythemia and post polycythemia 
vera myelofibrosis. 
Covariates HR  95% CI P value Risk  coefficient 
Beta 
Points assigned in 
the MYSEC-PM  
Age at diagnosis of SMF 1.07 1.05-1.09 <.0001 0.068 0.15 
Hemoglobin < 11 g/dL 2.3 1.6-3.3 <.0001 0.8 2 
Platelet < 150 x109/L 1.7 1.2-2.5 .006 0.5 1 
Circulating blast cells ≥ 3% 2.9 1.8-4.8 <.0001 1.1 2 
CALR-unmutated genotype 2.6 1.2-5.3 .001 0.9 2 
Constitutional symptoms 1.5 1.0-2.0 .03 0.4 1 
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